Natural Alternatives International Inc
NAII Nasdaq Medicinal Chemicals & Botanical Products Financials FY2017βFY2026
What Natural Alternatives International Inc does
No business description yet.
- Legal name
- NATURAL ALTERNATIVES INTERNATIONAL INC
- Fiscal year ends
- June 30, 2026
- Latest annual report
- 10-K Β· Sep 28, 2026
- Accession Β· CIK
- 0001437749-26-031343
0000787253
Revenue and margins
Natural Alternatives International Inc had $143M of revenue in fiscal 2026, up 9.7% on the year before.
Net income and earnings per share
Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was β$12.6M in fiscal 2026, β8.9% of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
Natural Alternatives International Inc returned $0.1M to shareholders in fiscal 2026. The diluted share count rose 1.4%.
Balance sheet
Cash, debt and the ratios that show how comfortably Natural Alternatives International Inc can carry it.
| Fiscal year end | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Cash and short-term investments | $21.8M | $13.6M | $12.0M | $12.3M | $7.4M |
| Current ratio | 3.2x | 3.6x | 2.6x | 2.1x | 1.7x |
| Quick ratio | 1.9x | 1.7x | 1.6x | 1.2x | 0.9x |
| Total assets | $146M | $134M | $162M | $152M | $126M |
| Total liabilities | $57.5M | $45.4M | $79.7M | $83.5M | $76.5M |
| Shareholders' equity | $88.5M | $88.8M | $82.6M | $68.4M | $50.0M |
| Net debt (β = net cash) | β | β | β | β | β |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
| Test | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 2 / 9 | 5 / 9 | 3 / 8 | 8 / 8 | 5 / 8 | 5 / 8 | 2 / 8 | 4 / 8 | 2 / 8 |
| Accruals ratio | β9.5% | 4.1% | β0.0% | β5.0% | β8.3% | β0.9% | β3.2% | β3.9% | β12.4% | β8.5% |
| Altman Z'' | 12.30 | 10.84 | 11.03 | 5.77 | 7.85 | 6.36 | 6.25 | 3.74 | 3.07 | 2.12 |
10 years of figures
US$ millions unless stated. Hover a ratio's name for its definition.
| Fiscal year | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $122M | $132M | $138M | $119M | $179M | $171M | $154M | $114M | $130M | $143M |
| Net interest income | β$0.0M | β$0.0M | β$0.0M | β$0.1M | β$0.1M | β$0.1M | β$0.5M | β$0.4M | β$0.9M | β$1.2M |
| Gross profit | $26.2M | $26.3M | $23.6M | $18.9M | $30.4M | $30.5M | $18.2M | $6.9M | $9.3M | $9.0M |
| Research and development | $1.6M | $1.5M | $1.8M | $1.8M | $1.9M | $2.5M | $2.1M | $1.9M | $1.8M | $2.3M |
| Operating income | $9.7M | $9.5M | $6.0M | β$1.5M | $13.7M | $13.7M | $4.7M | β$8.5M | β$8.7M | β$18.8M |
| Pretax income | $10.1M | $10.6M | $8.0M | β$1.7M | $12.1M | $13.7M | $3.6M | β$9.5M | β$10.7M | β$20.3M |
| Income tax | $2.9M | $5.6M | $1.4M | β$0.1M | $1.4M | $2.9M | $1.0M | β$2.2M | $2.8M | $0.4M |
| Net income | $7.2M | $5.1M | $6.5M | β$1.6M | $10.8M | $10.7M | $2.5M | β$7.2M | β$13.6M | β$20.7M |
| Diluted EPS | $1.09 | $0.73 | $0.92 | β$0.25 | $1.69 | $1.74 | $0.43 | β$1.23 | β$2.28 | β$3.43 |
| Diluted shares | 0.01B | 0.01B | 0.01B | 0.01B | 0.01B | 0.01B | 0.01B | 0.01B | 0.01B | 0.01B |
| Cash flow | ||||||||||
| Cash from operations | $14.1M | $1.8M | $6.6M | $3.7M | $20.8M | $11.9M | $7.0M | β$1.5M | $5.9M | β$8.9M |
| Capital expenditure | $5.4M | $4.1M | $5.3M | $4.5M | $5.1M | $26.5M | $13.5M | $3.0M | $3.6M | $3.7M |
| Free cash flow | $8.8M | β$2.2M | $1.2M | β$0.9M | $15.7M | β$14.6M | β$6.5M | β$4.5M | $2.3M | β$12.6M |
| Depreciation and amortization | $2.4M | $2.9M | $3.5M | $4.0M | $4.3M | $4.2M | $4.3M | $4.6M | $4.6M | $4.7M |
| Stock-based compensation | $1.0M | $1.3M | $1.7M | $1.7M | $1.4M | $1.0M | $1.0M | $1.2M | $1.0M | $0.6M |
| Share buybacks | $0.7M | $0.5M | $1.4M | $3.7M | $4.1M | $5.5M | $1.5M | $0.2M | $0.2M | $0.1M |
| Dividends and buybacks | $0.7M | $0.5M | $1.4M | $3.7M | $4.1M | $5.5M | $1.5M | $0.2M | $0.2M | $0.1M |
| Balance sheet | ||||||||||
| Cash and short-term investments | $27.8M | $23.6M | $25.0M | $30.5M | $32.1M | $21.8M | $13.6M | $12.0M | $12.3M | $7.4M |
| Total debt | $0.0M | $0.0M | $0.0M | β | β | β | β | β | β | β |
| Current assets | $51.7M | $65.2M | $71.4M | $79.0M | $80.3M | $76.7M | $57.0M | $61.6M | $59.3M | $65.4M |
| Current liabilities | $10.3M | $14.3M | $14.3M | $27.8M | $22.1M | $23.9M | $15.9M | $23.5M | $28.8M | $37.7M |
| Inventory | $13.7M | $23.6M | $26.0M | $28.0M | $27.0M | $32.5M | $29.7M | $24.2M | $24.9M | $30.8M |
| Property and equipment, net | $18.1M | $19.3M | $21.1M | $21.5M | $22.3M | $44.6M | $53.8M | $52.2M | $50.9M | $35.6M |
| Total assets | $72.6M | $85.2M | $93.5M | $120M | $120M | $146M | $134M | $162M | $152M | $126M |
| Total liabilities | $11.5M | $17.0M | $17.4M | $48.8M | $40.2M | $57.5M | $45.4M | $79.7M | $83.5M | $76.5M |
| Preferred stock | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Shareholders' equity | $61.1M | $68.2M | $76.1M | $71.4M | $80.1M | $88.5M | $88.8M | $82.6M | $68.4M | $50.0M |
| Margins | ||||||||||
| Gross margin | 21.5% | 19.9% | 17.0% | 15.9% | 17.1% | 17.8% | 11.8% | 6.0% | 7.2% | 6.3% |
| Operating margin | 8.0% | 7.2% | 4.3% | β1.3% | 7.7% | 8.0% | 3.1% | β7.5% | β6.7% | β13.2% |
| EBITDA margin | 9.9% | 9.4% | 6.8% | 2.1% | 10.1% | 10.4% | 5.8% | β3.4% | β3.2% | β9.9% |
| Net margin | 5.9% | 3.8% | 4.7% | β1.4% | 6.0% | 6.3% | 1.6% | β6.3% | β10.5% | β14.5% |
| FCF margin | 7.2% | β1.7% | 0.9% | β0.7% | 8.8% | β8.6% | β4.2% | β4.0% | 1.8% | β8.9% |
| Net interest share of revenue | β0.0% | β0.0% | β0.0% | β0.1% | β0.1% | β0.0% | β0.3% | β0.3% | β0.7% | β0.8% |
| Returns | ||||||||||
| Return on capital | 20.8% | 13.9% | 9.6% | β | β | β | β | β | β | β |
| Return on capital employed | 15.6% | 13.4% | 7.5% | β1.6% | 13.9% | 11.2% | 4.0% | β6.1% | β7.0% | β21.1% |
| Return on equity | 11.8% | 7.8% | 9.1% | β2.2% | 14.2% | 12.7% | 2.8% | β8.4% | β18.0% | β35.0% |
| Return on assets | 10.0% | 6.4% | 7.3% | β1.5% | 9.0% | 8.0% | 1.8% | β4.9% | β8.6% | β14.9% |
| Return on tangible equity | 11.8% | 7.4% | 8.6% | β2.3% | 13.4% | 12.1% | 2.8% | β8.7% | β19.8% | β41.4% |
| Growth | ||||||||||
| Revenue growth | β | 8.6% | 4.4% | β14.0% | 50.2% | β4.2% | β9.9% | β26.1% | 14.1% | 9.7% |
| Net income growth | β | β30.2% | 29.5% | β125.1% | β | β0.5% | β76.5% | β386.2% | β | β |
| EPS growth | β | β33.0% | 26.0% | β127.2% | β | 3.0% | β75.3% | β386.0% | β | β |
| FCF growth | β | β125.6% | β | β168.7% | β | β193.1% | β | β | β | β644.3% |
| Share count change | β | 3.5% | 3.1% | β5.7% | β4.7% | β3.5% | β4.5% | β0.1% | 1.3% | 1.4% |
| Financial health | ||||||||||
| Net debt / EBITDA | β2.3x | β1.9x | β2.7x | β | β | β | β | β | β | β |
| Debt / equity | 0.0x | 0.0x | 0.0x | β | β | β | β | β | β | β |
| Current ratio | 5.0x | 4.6x | 5.0x | 2.8x | 3.6x | 3.2x | 3.6x | 2.6x | 2.1x | 1.7x |
| Quick ratio | 3.7x | 2.9x | 3.2x | 1.8x | 2.4x | 1.9x | 1.7x | 1.6x | 1.2x | 0.9x |
| Capital allocation | ||||||||||
| Capex / revenue | 4.4% | 3.1% | 3.9% | 3.8% | 2.9% | 15.5% | 8.8% | 2.7% | 2.8% | 2.6% |
| Stock comp / revenue | 0.8% | 1.0% | 1.2% | 1.4% | 0.8% | 0.6% | 0.7% | 1.1% | 0.8% | 0.4% |
| Payouts / FCF | 8.1% | β | 110.5% | β | 26.4% | β | β | β | 7.7% | β |
| Quality scores | ||||||||||
| Piotroski F-score | β | 2.0 | 5.0 | 3.0 | 8.0 | 5.0 | 5.0 | 2.0 | 4.0 | 2.0 |
| Altman Z'' | 12.3 | 10.8 | 11.0 | 5.8 | 7.8 | 6.4 | 6.2 | 3.7 | 3.1 | 2.1 |
| Accruals ratio | β9.5% | 4.1% | β0.0% | β5.0% | β8.3% | β0.9% | β3.2% | β3.9% | β12.4% | β8.5% |
Source: SEC EDGAR XBRL filings (CIK 0000787253). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.